预约演示
更新于：2025-07-31
Mecobalamin
甲钴胺
更新于：2025-07-31
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1987-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C63H91CoN13O14P |
InChIKeyROWAQRTUUUIVDZ-FGIXMQGJSA-M |
CAS号13422-55-4 |
关联
62
项与 甲钴胺 相关的临床试验NCT06813274
Multicenter, Double Blind, Randomized, Placebo-controlled Trial to Exploring the Role of Eye-Brain Multimodal Imaging in Diagnosing and Treating Neurovascular Coupling Impairment in Diabetes Mellitus
CTRI/2024/10/075367
A prospective, open-label, randomized, comparative clinical trial to assess theefficacy and safety of a novel Methylcobalamin Nasal Spray (NASO B12) or oral B12 supplementation in the treatment of subjects with vitamin B12 deficiencyas well as to evaluate the duration of efficacy - Nill
CTRI/2024/10/074789
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence studyof Pregabalin (PR), Methylcobalamin and Nortriptyline Hydrochloride Tablets (75 mg+1500 mcg+10 mg) of Unison Pharmaceuticals Private Limited with NeuGaba® MN Tablets [Pregabalin (PR), Methylcobalamin and Nortriptyline Hydrochloride Tablets (75 mg+1500 mcg+10mg)] Manufactured By: Synokem Pharmaceuticals Limited; Marketed By: Sun Pharma Laboratories Limited in healthy adult human subjects under fasting conditions. - NIL
100 项与 甲钴胺 相关的临床结果
登录后查看更多信息
100 项与 甲钴胺 相关的转化医学
登录后查看更多信息
100 项与 甲钴胺 相关的专利（医药）
登录后查看更多信息
2,119
项与 甲钴胺 相关的文献（医药）2025-09-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Methylcobalamin-loaded ultra-flexible liposomes: a nanocarrier approach for modulating melanocyte homeostasis and addressing pigmentation imbalances
Article
作者: Erkut, Tülay Selin ; Gümüşderelioğlu, Menemşe ; Coşkun, Sema
Although various therapeutic approaches have been developed for hyperpigmentation, the reliability and efficacy of these treatments remain controversial. This study investigates the effect of methylcobalamin encapsulated in ultra-flexible liposomes on melanocyte homeostasis and evaluates its antioxidant potential for treating pigmentation disorders. Ultra-flexible liposomes with a final lipid concentration of 10 mM were prepared using soy phosphatidylcholine and sodium cholate via the thin-film hydration method. The particle sizes of blank and methylcobalamin-loaded liposomes were 118 ± 9 nm and 124 ± 3 nm, respectively, demonstrating their suitability for in vitro drug release, permeability studies and biomedical applications. Dynamic Light Scattering analysis confirmed the formation of ultra-flexible liposomes with a negative surface charge, similar to cell membranes. Stability studies showed that both particle size and zeta potential remained stable for up to 4 weeks, indicating the structural integrity of the formulation. Approximately 70 % of the encapsulated methylcobalamin was released within 24 h, with an encapsulation efficiency of around 42 %. These liposomes, with a deformability index close to 1, penetrated deeper into the epidermis and dermis of porcine ear skin compared to the free drug. Cell culture studies demonstrated the biocompatibility of the liposomes, with no cytotoxic effects on human dermal fibroblasts and a high uptake rate by human dermal melanocytes. In vitro experiments on melanocyte cells showed a reduction in melanin content, tyrosinase activity, and reactive oxygen species levels, indicating the antioxidant potential of methylcobalamin. In conclusion, methylcobalamin-loaded ultra-flexible liposomes appear to be promising nanocarriers for the targeted treatment of pigmentation disorders.
2025-07-11MEDICINE
Central nervous system superficial siderosis: A case report and literature review
Review
作者: Li, Hong ; Xu, Qun ; Di, Mingxue ; Wen, Shengnan ; Yang, Guang
Rationale::
Superficial siderosis of the central nervous system (SSCNS) is a rare condition characterized by iron deposition on the surface tissues of the central nervous system. However, the diagnosis and treatment of diseases lack uniform principles.
Patient concerns::
A 64-year-old woman who was admitted to our hospital with progressive difficulty walking.
Diagnoses::
Based on the patient’s history of traumatic lumbar fractures, progressive hearing loss, and physical examination findings indicative of cerebellar ataxia, sensorineural deafness, and bilateral pyramidal tract involvement, combined with susceptibility-weighted imaging revealing linear low-signal intensities on the surfaces of the cerebral hemispheres, sulci, and spinal cord, a diagnosis of SSCNS was made.
Interventions::
The patient received treatment with Ginkgo biloba leaf extract tablets, mecobalamin, and vitamin B1.
Outcomes::
Her symptoms remained stable.
Lessons::
A literature review has revealed that most patients with SSCNS exhibit diverse clinical manifestations. Clinicians should consider SSCNS in patients presenting with hearing impairment and gait ataxia, particularly those receiving anticoagulant therapy, brain injury, or surgical intervention. The clinical manifestations, imaging findings, management strategies, and prognosis of these cases are discussed, highlighting the key roles of magnetic resonance imaging and susceptibility-weighted imaging in establishing a definitive diagnosis. In addition, the importance of a multidisciplinary team approach in providing holistic care for individuals has been emphasized. Clinicians are advised to investigate SSCNS in patients with hearing impairment and gait ataxia, particularly in those with a history of brain injury or surgery, using magnetic resonance imaging results.
2025-06-23Scientific Reports
Green and white analytical approach for parallel quantification of gabapentin and methylcobalamin in medicinal products using inventive RP-HPLC technique.
Article
作者: Mohamed, Mahmoud A ; Binsaleh, Ammena Y ; Saleh, Sayed M ; Alminderej, Fahad M ; Alsehli, Bandar R ; Mahgoub, Samar M
A simple, selective, and environmentally sustainable RP-HPLC method was developed for simultaneous quantification of gabapentin (GAB) and Methylcobalamin (MET) in pharmaceutical products. Separation was achieved on a Zorbax Eclipse C8 column (150 × 4.6 mm, 3.5 μm) using a green mobile phase of potassium phosphate buffer (pH 6.9)/acetonitrile (95:5 v/v) at 2.0 mL/min, with detection at 210 nm. Total analysis time was 10 min with 100 µL injection volume. The method showed excellent linearity (3-50 µg/mL; R² > 0.9998), LODs (0.60-0.80 µg/mL), and LOQs (2.00-2.50 µg/mL). Environmental sustainability was validated by multiple metrics: AGREE (0.70), AGREEprep (0.71), and Analytical Eco-Scale (80), confirming superior greenness. Forced degradation studies demonstrated stability-indicating capability per ICH guidelines. This eco-friendly approach provides a reliable solution for quality control of GAB/MET formulations while minimizing environmental impact.
100 项与 甲钴胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌萎缩侧索硬化 | 日本 | 2024-09-24 | |
| 周围神经系统疾病 | 日本 | 1987-04-16 | |
| 神经痛 | 中国 | - | |
| 神经炎 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 甲基丙二酸血症 | 临床前 | 美国 | 2024-10-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 130 | 醖蓋範窪網顧艱積積網(積壓鬱鹽繭範顧艱鹽觸) = 夢淵襯廠製顧蓋蓋鹹壓 構鑰餘醖襯鏇壓壓憲製 (鹹窪壓積艱選醖襯遞壓 ) | 积极 | 2022-05-09 | |||
Placebo | 醖蓋範窪網顧艱積積網(積壓鬱鹽繭範顧艱鹽觸) = 鹹觸製衊衊鑰窪憲願鏇 構鑰餘醖襯鏇壓壓憲製 (鹹窪壓積艱選醖襯遞壓 ) | ||||||
临床2期 | - | 願糧鬱鬱淵顧醖壓構壓(構鏇夢艱餘範夢製糧夢) = 壓夢艱鬱選簾築網窪構 壓淵鑰膚網鏇網簾廠膚 (鏇醖襯顧鬱觸鬱襯夢窪 ) | 积极 | 2021-07-19 | |||
願糧鬱鬱淵顧醖壓構壓(構鏇夢艱餘範夢製糧夢) = 襯壓廠衊顧壓齋膚觸鹹 壓淵鑰膚網鏇網簾廠膚 (鏇醖襯顧鬱觸鬱襯夢窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用